Iron Orotate Tetrahydrate

Iron orotate tetrahydrate is a chelated iron compound in which ferrous iron is bound to orotic acid in a tetrahydrate crystal form, providing approximately 13.0–13.8% elemental ferrous iron by weight. It belongs to the orotate mineral salt class theorized to enhance membrane transport via orotic acid's affinity for cellular uptake pathways, though no human clinical trials have confirmed efficacy or superiority over other iron forms.

Origin & History

Iron Orotate Tetrahydrate is a synthetic coordination compound where ferrous iron (Fe²⁺) is chelated with two orotate ligands derived from orotic acid, a pyrimidine carboxylic acid. It is manufactured industrially as a metal-organic complex appearing as a yellowish-brown crystalline powder, with no natural origin from specific organisms or plants.

Historical & Cultural Context

No historical or traditional medicinal uses are documented for Iron Orotate Tetrahydrate. It is described solely as a modern dietary supplement ingredient with no traditional medicine heritage.

Health Benefits

• No clinically proven health benefits - no human trials documented in available research
• Functions as an iron supplement source providing 13.0-13.8% ferrous iron content
• No evidence of specific advantages over other iron forms in humans
• Animal toxicity data exists but no efficacy studies available
• Theoretical use for iron deficiency requires clinical validation

How It Works

Iron orotate tetrahydrate dissociates in the gastrointestinal tract to release ferrous iron (Fe²⁺) and orotic acid (uracil-4-carboxylic acid). Ferrous iron is absorbed primarily via the divalent metal transporter 1 (DMT1) in duodenal enterocytes, where it enters systemic circulation and binds to transferrin for delivery to tissues requiring iron-dependent enzymes such as hemoglobin, myoglobin, and cytochromes. The orotic acid moiety is theorized by proponents to facilitate passive diffusion across lipid membranes, potentially improving intracellular iron delivery, but this mechanism has not been validated in controlled human pharmacokinetic studies.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Iron Orotate Tetrahydrate were found in the research sources. Limited data exists only from animal toxicity studies with no PMIDs or specific study details available.

Clinical Summary

No published human clinical trials investigating iron orotate tetrahydrate for efficacy, bioavailability, or therapeutic outcomes could be identified in available research literature. Existing data is limited to animal toxicity studies, which characterize safety thresholds rather than therapeutic benefit. Without randomized controlled trials, sample size data, or quantified clinical endpoints in humans, no evidence-based conclusions can be drawn about its effectiveness for iron deficiency anemia or any other condition. The evidence base is therefore rated extremely low, and clinical use should be guided by better-studied iron forms such as ferrous sulfate or ferrous bisglycinate.

Nutritional Profile

Iron Orotate Tetrahydrate is a chelated mineral compound consisting of ferrous iron (Fe²⁺) bound to orotic acid (vitamin B13 precursor) with four water molecules of crystallization. Iron content: 13.0–13.8% elemental ferrous iron by molecular weight, derived from its molecular formula FeC₅H₄N₂O₄·4H₂O (molecular weight approximately 404 g/mol). Contains no macronutrients (zero protein, fat, or carbohydrate contribution at supplemental doses). Orotic acid component (C₅H₄N₂O₄) constitutes approximately 60–62% of the anhydrous compound by mass and is a pyrimidine precursor involved in nucleotide biosynthesis pathways. No dietary fiber, vitamins, or secondary micronutrients present. Bioavailability: ferrous (Fe²⁺) oxidation state is the more bioavailable form of iron compared to ferric (Fe³⁺); the orotate chelation is theorized to enhance mucosal transport by protecting iron from precipitation in alkaline intestinal environments, though this mechanism has not been confirmed in human clinical trials. The tetrahydrate form releases water of crystallization upon dissolution, yielding the active iron orotate complex. No documented comparative bioavailability data versus ferrous sulfate, ferrous bisglycinate, or other standard iron supplement forms in humans. At typical supplemental iron doses (18–65 mg elemental iron), a serving would require approximately 130–500 mg of the tetrahydrate compound based on its 13–13.8% iron content.

Preparation & Dosage

No clinically studied dosage ranges are available as no human trials have been documented. Commercial forms contain 13.0-13.8% ferrous iron content. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Vitamin B12, Folate, Copper, Vitamin A

Safety & Interactions

Because no dedicated human safety trials exist for iron orotate tetrahydrate, its side effect profile is inferred from the broader class of oral iron supplements, which commonly cause gastrointestinal adverse effects including nausea, constipation, and dark stools, particularly at doses exceeding 45 mg elemental iron per day. Orotic acid, the chelating ligand, has been independently associated with hepatic lipid accumulation and orotic aciduria in animal models at high doses, raising a theoretical concern not yet evaluated in humans. Iron supplements broadly interact with tetracycline and quinolone antibiotics, levothyroxine, and calcium-containing products by forming insoluble complexes that reduce absorption of both the drug and the iron. Pregnancy safety has not been specifically evaluated for this compound; standard supplemental iron is considered safe in pregnancy under medical supervision, but iron orotate tetrahydrate should not be substituted without clinical guidance.